Tag: Policy

The FDA views aging as an inevitability, not a medical target. However, with Life Biosciences moving the first cellular reprogramming therapy into human trials this year, things might be changing there. If this technique works in resetting the biological age of the human eye, the entire multibillion-dollar longevity industry could move to the center of...

The last installment in our end-of-year series of expert roundups might be the least flashy, but it is arguably no less important than the previous ones dedicated to longevity biotech and geroscience. Public advocacy is a powerful lever. To quote Abraham Lincoln: “Public sentiment is everything. With it, nothing can fail; against it, nothing can...

The idea of living longer, healthier lives thanks to rejuvenation biotechnology has steadily become more common. Gradually increasing numbers of articles are discussing this idea, especially as science is starting to catch up and may eventually even deliver on it. With that in mind, I was pleasantly surprised this week to be greeted by an...

Two people nearly died, and several more sought treatment, after receiving peptide injections at the last RAADfest in Las Vegas. We might not know what happened until the ongoing investigations are concluded, but we asked several experts to share their thoughts on the broader context of unproven “rejuvenation therapies.” The nightmare scenario Admittedly, progress in...

In this Lifespan interview, we speak with Gabriel Cian, founder of the 2060 Longevity Forum, about how his background in software shaped his views on healthspan innovation, the forum’s approach to scientific and investment credibility, and what he sees as the biggest bottlenecks and opportunities facing the field of longevity today. Hi, Gabriel. Let’s start...

Just several years ago, longevity conferences were few and far between. Today, there’s no shortage of them. Happening regularly around the globe, they foster scientific debate and showcase geroscience advances to the world while energetically discussing longevity biotech and regulations. However, one important subfield, working with public opinion and politicians, has been all but excluded...